chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by RA for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Injection site rash, Joint swelling, Rash erythematous
Clinical narrative: Three days after receiving vaccination, patient started to experience swollen wrists and joints. She experienced severe joint pain. She also developed a rash red rash from her injection site to her elbow.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved  for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Severe Hives started appearing on 10th day after vaccine.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose normal, Dizziness, Dry mouth, Fatigue, Thirst
Clinical narrative: Day after vaccination I experienced extreme fatigue, severe dry mouth, excessive thirst and dizziness
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: I have had persistent ringing in my ears for six months
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Arthritis, Condition aggravated, Musculoskeletal stiffness, Pain in extremity
Clinical narrative: P Joint paint in left and right wrists and fingers. Visited primary care Dr. His diagnosis suggested arthritis. Treatment suggested was warm water in am, cold water in pm. Have had stiffness in hands prior to booster, but after booster was much worse with no relief.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: X-ray limb abnormal
Clinical narrative: P Joint paint in left and right wrists and fingers. Visited primary care Dr. His diagnosis suggested arthritis. Treatment suggested was warm water in am, cold water in pm. Have had stiffness in hands prior to booster, but after booster was much worse with no relief.
Age: 65.0
Sex: M
Vaccine: PPV
Symptoms: Hypersensitivity, Induration, Limb mass, Peripheral swelling
Clinical narrative: I saw my doctor on 5/13/2022 for a wellness check as I turned 65 years old this past month. I was given the Pneumovax 23 vaccine and within several hours, while driving home. developed a very large, hard lump on my left upper arm. Later it was progressing down my arm to my elbow. I phoned my doctor who told me to immediately go to the emergency room, which I did. After several hours they released me thinking that it was simply an allergic reaction. It did not respond to Benadryl. The following morning it is continuing to progress and my left arm is nearly twice the size of my right arm. As instructed, I took Benadryl but it is having no impact and is not relieving the possible allergic reaction to the vaccine. I am reluctant to return to the emergency room and spend another $120. only to be told the same thing. I am 65 years old, single, with a disability and reside alone where I have no family. My closest friend is immunocompromised due to a kidney transplant so I do not want him exposed to any illnesses at the emergency room. Having worked all my life and traveled extensively, I have always been vaccinated, especially before traveling to another country. I have never had an adverse reaction to a vaccine. I am not am alarmist, however this, being quite out of the ordinary, is concerning. All of my vital signs both initially at my doctors appointment and in the emergency room were normal. My blood pressure. weight, and vitals are all normal. I do not drink or smoke and have no other contributing medical factors that would have caused this.
Age: 5.0
Sex: M
Vaccine: HEP
Symptoms: Erythema, Eye swelling, Pruritus, Swelling face
Clinical narrative: after 2nd dose of Hepatitis B vaccine, my 5 year old son developed swelling around the left eye, a few days later, developed full blown facial swelling, redness and itching
Sex: U
Vaccine: DTAPHEPBIP
Symptoms: Wrong product administered
Clinical narrative: Pt due for Dtap vax but received Pediarix.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, Product storage error
Clinical narrative: Pt. received dose of Moderna from a vial that was outside the discard timeframe. Vial was still stored at proper storage temp. Moderna manuf. notified. Due to, proper storage & no other negative factors, per Moderna vaccine dose "Maintained activity against COVID-19". Dose valid Per Moderna. Doses increased risk for microbial infection the father outside the discard window as it is for MDV. No known injury to patient.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Balance disorder, Dizziness, Tinnitus
Clinical narrative: Tinnitus Dizzy Lightheaded Balance issuesNone
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Speech disorder, Swollen tongue
Clinical narrative: Narrative: Pt received the vaccine approx 2-3 min later c/o tongue swelling unable to complete sentences. Denied SOB, rash, or arm swelling. Pulse ox 100%, pulse rate 80"s. declined epi pen sent to the ED for evaluation
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Dry mouth, Hypoaesthesia oral, Throat tightness
Clinical narrative: Narrative: 11:31 Patient arrived in observation area for 30 minutes observation  status post first Moderna vaccination. At 1155 patients began complaining of feeling of mouth dryness, fullness in back of her throat and numbness in her lips. Patient was assess for symptoms of severe allergic reaction. She reported no difficulty breathing, or swallowing, dizziness, weakness or rash noted. 11:57 Vital signs stable 97.9. 18, 78, 143/95, 100% r/a. monitored until medics arrived. Patient decline use of EPI.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza like illness
Clinical narrative: Narrative: patient reported flu-like symptoms for "months" after vaccination
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Asthma, Chest discomfort, Chest pain, Condition aggravated
Clinical narrative: Narrative: 74 yo M with PMH of asthma, received COVID-19 booster (3rd dose Pfizer) and within 4 hours had chest discomfort. Did not have any reaction to first two covid-19 vaccine doses. Evaluated by pulmonologist following 3rd dose,  pulmonologist attributed chest pain to worsening asthma. Symptoms resolved within 1 month.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Angioedema, Extra dose administered, Interchange of vaccine products, Pruritus
Clinical narrative: Narrative:  62 yo F with HF. Received J&J vaccine booster (dose#2) on  4/20/22 at 14:00. Later that evening, patient had angioedema. Note, the patient had reported mild angioedema of the lip and itching the evening of 4/20/22 after  vaccine given. Benadryl 25mg x1 was given and helped. Only new med was clotrimazole (without dyes per MD note). Drank a few Boosts that pt later realized contains soy of which she is allergic. Later on 4/21/22 in the evening, sx of angioedema were improved. Previously received J&J vaccine (dose#1) on 11/30/21 without reported complication. Had previous reaction of angioedema  to 1 dose of Moderna vaccine (given 1/29/21). Angioedema following Moderna vaccine was tongue/lip/facial swelling. This occurred 3-4 hours after the the dose was given. Sx improved following dose of Benadryl 25mg po. Also c/o R arm injection site swelling, extreme fatigue. Allergist evaluated the patient and said OK to get 2nd dose of Moderna vaccine but patient declined.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Narrative:  Hospitalized 5/5/22 to 5/9/22.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: Narrative: None stated.
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Asthenia, COVID-19, COVID-19 pneumonia, Hypoxia, Pyrexia
Clinical narrative: Narrative:  The patient received two doses of Pfizer COVID 19 Vaccine in Jan/Feb 2021. The patient tested positive for COVID 19 on 2 Feb 2022. The patient presented to the ED with weakness, fever, and hypoxia. The patient was admitted to the hospital with covid pneumonia and sepsis. The patient was treated with remdesivir and dexamethasone. The patient was discharged on 7 Feb 2022. Reported per EUA.
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test positive, Sepsis
Clinical narrative: Narrative:  The patient received two doses of Pfizer COVID 19 Vaccine in Jan/Feb 2021. The patient tested positive for COVID 19 on 2 Feb 2022. The patient presented to the ED with weakness, fever, and hypoxia. The patient was admitted to the hospital with covid pneumonia and sepsis. The patient was treated with remdesivir and dexamethasone. The patient was discharged on 7 Feb 2022. Reported per EUA.
Age: 74.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Acute kidney injury, COVID-19, Fall, Rhabdomyolysis, SARS-CoV-2 test positive
Clinical narrative: Narrative: The patient received three doses of Moderna COVID 19 Vaccine in Apr,May,Sep 2021. The patient tested positive for COVID 19 on 1 Feb 2022. The patient presented to the ED after a fall. The patient was admitted with acute kidney injury, rhabdomyolysis, elevated troponin, and covid 19. The patient was treated with fluids and electrolytes. The patient was discharged on 14 Feb 22 in stable condition. Reported per EUA.
Age: 74.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Troponin increased
Clinical narrative: Narrative: The patient received three doses of Moderna COVID 19 Vaccine in Apr,May,Sep 2021. The patient tested positive for COVID 19 on 1 Feb 2022. The patient presented to the ED after a fall. The patient was admitted with acute kidney injury, rhabdomyolysis, elevated troponin, and covid 19. The patient was treated with fluids and electrolytes. The patient was discharged on 14 Feb 22 in stable condition. Reported per EUA.
Age: 49.0
Sex: M
Vaccine: FLUX
Symptoms: Pain in extremity
Clinical narrative: Narrative:  Pt. developed arm soreness shortle rorj
Age: 59.0
Sex: M
Vaccine: VARZOS
Symptoms: Blood glucose increased, Chills, Cough, Dyspnoea, Hyperhidrosis
Clinical narrative: Narrative:  Per mom clinic records patient reported day after vaccine (On 1/15/22) experiencing nausea and vomiting, he also developed chills, sweats, he also had a cough and has felt short of breath at times. , He reported arm sore but no redness or warmth. He is diabetic, his blood sugars are initially on the 400s over the weekend. Did have subsequent negative COVID test on 1/18/22.
Age: 59.0
Sex: M
Vaccine: VARZOS
Symptoms: Nausea, Pain in extremity, SARS-CoV-2 test negative, Vomiting
Clinical narrative: Narrative:  Per mom clinic records patient reported day after vaccine (On 1/15/22) experiencing nausea and vomiting, he also developed chills, sweats, he also had a cough and has felt short of breath at times. , He reported arm sore but no redness or warmth. He is diabetic, his blood sugars are initially on the 400s over the weekend. Did have subsequent negative COVID test on 1/18/22.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea, Immunisation reaction, Nausea, Swelling, Urticaria
Clinical narrative: Narrative: Per PCP note, upon discharge from hospital, 1/20/22: s/p COVID booster- then spent 8 days in the hospital after having terrible hives 6 days after getting the booster-he had severe n/v/d and hives and swelling Was in the ER at Facility for likely side effects to the COVID booster Moderna with n/v/d and severe swelling and hives. Was hospitallized for 8 days and was on 100 mg of Prednisone after being on Solumedrol. Still on Zyrtec 40  mg daily and Hydroxyzine 75 mg qhs and Famotidine 40 mg qhs. Seeing the private immunologist today, and saw over 12 specialists while hospitalized. Still having side effects from the steroids even though he completed them 2 days ago. Assessment/Plan: 1. S/P hospitalization for 8 days secondary to COVID booster reaction with hives and swelling. Seeing private immunologist.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Narrative: Per PCP note, upon discharge from hospital, 1/20/22: s/p COVID booster- then spent 8 days in the hospital after having terrible hives 6 days after getting the booster-he had severe n/v/d and hives and swelling Was in the ER at Facility for likely side effects to the COVID booster Moderna with n/v/d and severe swelling and hives. Was hospitallized for 8 days and was on 100 mg of Prednisone after being on Solumedrol. Still on Zyrtec 40  mg daily and Hydroxyzine 75 mg qhs and Famotidine 40 mg qhs. Seeing the private immunologist today, and saw over 12 specialists while hospitalized. Still having side effects from the steroids even though he completed them 2 days ago. Assessment/Plan: 1. S/P hospitalization for 8 days secondary to COVID booster reaction with hives and swelling. Seeing private immunologist.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: Narrative:  rash/itching resolving at time seen by PCP (11-3-2021). Trial of topical Sarna ordered.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Anaphylactic shock
Clinical narrative: Narrative: Historical ADE - pt. received first dose of Moderna vaccine on 2/1/2021 and went into anaphylactic shock. Further information not available concerning lot number, etc. as pt. not administered first dose at Agency. ADR documented for informational purposes.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Chills, Cough, Diarrhoea
Clinical narrative: Headache, Myalgia, Fever, CoughWheeze, Diarrhea, NauseaVomiting, right arm swelling from injection site to wrist, chills, sweats, dizziness, sore throat, loss of taste/smell, SOB Narrative: Tested for COVID, RSV, Flu B, Flu A on 5/9/22 and all were negative.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Dyspnoea, Headache, Hyperhidrosis, Influenza A virus test negative
Clinical narrative: Headache, Myalgia, Fever, CoughWheeze, Diarrhea, NauseaVomiting, right arm swelling from injection site to wrist, chills, sweats, dizziness, sore throat, loss of taste/smell, SOB Narrative: Tested for COVID, RSV, Flu B, Flu A on 5/9/22 and all were negative.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza B virus test, Injection site swelling, Myalgia, Nausea, Oropharyngeal pain
Clinical narrative: Headache, Myalgia, Fever, CoughWheeze, Diarrhea, NauseaVomiting, right arm swelling from injection site to wrist, chills, sweats, dizziness, sore throat, loss of taste/smell, SOB Narrative: Tested for COVID, RSV, Flu B, Flu A on 5/9/22 and all were negative.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Respiratory syncytial virus test, SARS-CoV-2 test negative, Vomiting, Wheezing
Clinical narrative: Headache, Myalgia, Fever, CoughWheeze, Diarrhea, NauseaVomiting, right arm swelling from injection site to wrist, chills, sweats, dizziness, sore throat, loss of taste/smell, SOB Narrative: Tested for COVID, RSV, Flu B, Flu A on 5/9/22 and all were negative.
Age: 0.08
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain
Clinical narrative: Headache BODY ACHES, CHILLS, FATIGUE Narrative:
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chest discomfort, Fatigue, Myalgia, Pain
Clinical narrative: Myalgia, Arthralgia, Fever, SkinRash, Rash, UrticariaPruritus, "Generalized vaccine symptoms such as body aches, tiredness, etc starting aroun 1400 that day. Slight chest tightness and low grade fever-100.3 that evening 2000. Rash/hives on hands/chest/arms 5/13/2022 1100 - came to Occupational health office: Narrative:
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Pyrexia, Rash, Urticaria
Clinical narrative: Myalgia, Arthralgia, Fever, SkinRash, Rash, UrticariaPruritus, "Generalized vaccine symptoms such as body aches, tiredness, etc starting aroun 1400 that day. Slight chest tightness and low grade fever-100.3 that evening 2000. Rash/hives on hands/chest/arms 5/13/2022 1100 - came to Occupational health office: Narrative:
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Injection site pain, Myalgia
Clinical narrative: Headache, Myalgia, chills, tenderness at injection site Narrative: NA
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Injection site pain
Clinical narrative: Headache tenderness at injection site Narrative:
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Nausea
Clinical narrative: headache, nausea, muscle ache Narrative:
Age: 73.0
Sex: M
Vaccine: FLUA4
Symptoms: Unevaluable event
Clinical narrative: Narrative:
Age: 71.0
Sex: M
Vaccine: FLUX
Symptoms: Guillain-Barre syndrome
Clinical narrative: Narrative: Pt. developed Guillain Barre attributed to influenza vaccine he received from private Md (outside clinic) in November 2019. Pt sees outside clinic private MD. This is a historical report from clinic primary care provider. No info known of date and place and brand of influenza vaccine given in 11/2019.
Age: 79.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Anaemia, Asthenia, Atrial fibrillation, COVID-19, COVID-19 pneumonia
Clinical narrative: Narrative: The patient received three doses of Pfizer COVID 19 Vaccine in Jan,Feb,Oct 2021. The patient tested positive for COVID 19 on 8 Feb 2022. The patient presented to the ED with shortness of breath and weakness. The patient was admitted on 8 Feb 2022 with covid pneumonia, afib, and anemia. The patient was treated with remdesivir and dexamethasone. The patient's condition did not improve. The patient was referred to hospice care on 4 March 2022. The patient died on 14 March 2022 of respiratory failure and covid pneumonia. Reported per EUA.
Age: 79.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Death, Dyspnoea, Respiratory failure
Clinical narrative: Narrative: The patient received three doses of Pfizer COVID 19 Vaccine in Jan,Feb,Oct 2021. The patient tested positive for COVID 19 on 8 Feb 2022. The patient presented to the ED with shortness of breath and weakness. The patient was admitted on 8 Feb 2022 with covid pneumonia, afib, and anemia. The patient was treated with remdesivir and dexamethasone. The patient's condition did not improve. The patient was referred to hospice care on 4 March 2022. The patient died on 14 March 2022 of respiratory failure and covid pneumonia. Reported per EUA.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pityriasis rosea, Rash, Skin lesion
Clinical narrative: Booster shot was administered on 4/25/2022 at 10:45 am. Rash occurred on 5/6/2022. Initially an annular lesion appeared on the left forearm (Harold Patch). The rash then spread to the arms, neck, chest, back, abdomen, and upper thighs. The rash consisted of oval lesions following the lines of cleavage. The diagnosis is Pityriasis Rosea. Patient was misdiagnosed by her PCP and given a Medrol dose pack prior to her visit at my Dermatology office on 5/19/2022.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: Did you/the patient previously receive a COVID-19 Vaccine?: Yes; Did you/the patient previously receive a COVID-19 Vaccine?: Yes; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and on 21May2021 at 14:00 as dose 2, single (Lot number: ER8735) at the age of 46 years, in right arm for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: LISINOPRIL.  The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant) all with onset May2022, outcome "unknown" and all described as "Did you/the patient previously receive a COVID-19 Vaccine?: Yes". Therapeutic measures were taken as a result of covid-19, drug ineffective.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 10.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Seizure, Syncope
Clinical narrative: Code 99 called to Dental clinic at 254 PM.  Patient/child found on floor on LEFT side, head supported via RN, Drs at bedside to support child on left side for airway management. Child "shaking" from head to toes, no incontinence of urine or vomit, no clenched jaw. Airway open/coloring pink/warm.  Patient does not respond to any verbal commands, moaning nonstop during seizure activity.  Per Dr:  event has been in progress 2 minutes prior to team arrival  At 254 PM (started @ 2:52).  Skin warm/pink, teeth/jaw are not clenched, mouth open. Placed 2 L n/c oxygen on patient per provider request.  BS via glucometer = 141 Unable to get VS d/t shaking/seizure. EMS called via dental staff.
Age: 10.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cardio-respiratory arrest, Moaning, Seizure, Tremor, Unresponsive to stimuli
Clinical narrative: Code 99 called to Dental clinic at 254 PM.  Patient/child found on floor on LEFT side, head supported via RN, Drs at bedside to support child on left side for airway management. Child "shaking" from head to toes, no incontinence of urine or vomit, no clenched jaw. Airway open/coloring pink/warm.  Patient does not respond to any verbal commands, moaning nonstop during seizure activity.  Per Dr:  event has been in progress 2 minutes prior to team arrival  At 254 PM (started @ 2:52).  Skin warm/pink, teeth/jaw are not clenched, mouth open. Placed 2 L n/c oxygen on patient per provider request.  BS via glucometer = 141 Unable to get VS d/t shaking/seizure. EMS called via dental staff.
Age: 56.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Pain, Pyrexia, Vaccination site pain
Clinical narrative: PCR test result at 7pm on 16-May came to be COVID +ve.; PCR test result at 7pm on 16-May came to be COVID +ve.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56-year-old male patient received BNT162b2 (BNT162B2), on 07Apr2022 at 11:00 as dose 4 (booster), single (Lot number: FL3197) at the age of 56 years intramuscular, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "high LDL-C" (unspecified if ongoing). Concomitant medication(s) included: LIPITOR.  The following information was reported: DRUG INEFFECTIVE (medically significant) with onset May2022, outcome "recovering", COVID-19 (medically significant) with onset 16May2022, outcome "recovering" and all described as "PCR test result at 7pm on 16-May came to be COVID +ve.". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (14May2022) Negative, notes: At home kit gave me COVID -ve result on 14th; (16May2022) Positive, notes: PCR test result at 7pm on 16May came to be COVID +ve. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  Clinical Course: If other vaccine in four weeks was reported as no. Other medications in two weeks were reported as Lipitor 20 mg and multi vitamins. If covid prior vaccination was reported as no. If covid tested post vaccination was reported as no. No Known allergies.
Age: 56.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: PCR test result at 7pm on 16-May came to be COVID +ve.; PCR test result at 7pm on 16-May came to be COVID +ve.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56-year-old male patient received BNT162b2 (BNT162B2), on 07Apr2022 at 11:00 as dose 4 (booster), single (Lot number: FL3197) at the age of 56 years intramuscular, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "high LDL-C" (unspecified if ongoing). Concomitant medication(s) included: LIPITOR.  The following information was reported: DRUG INEFFECTIVE (medically significant) with onset May2022, outcome "recovering", COVID-19 (medically significant) with onset 16May2022, outcome "recovering" and all described as "PCR test result at 7pm on 16-May came to be COVID +ve.". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (14May2022) Negative, notes: At home kit gave me COVID -ve result on 14th; (16May2022) Positive, notes: PCR test result at 7pm on 16May came to be COVID +ve. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  Clinical Course: If other vaccine in four weeks was reported as no. Other medications in two weeks were reported as Lipitor 20 mg and multi vitamins. If covid prior vaccination was reported as no. If covid tested post vaccination was reported as no. No Known allergies.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: pain in her arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 57-year-old female patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for Covid-19 immunization, reaction(s): "Pain in arm". The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "pain in her arm".  Follow-up (11May2022): This is a spontaneous follow-up report from a contactable consumer. Updated information: reporter and patient information; country of the reporter, where the event occurred, where the drug was obtained, country of authorization of drug was updated . All information reported in manufacturer report number 202200655631 will be reported under manufacturer report number 202200704886.   The information on the batch/lot number for (BNT162B2), has been requested and will be submitted if and when received.
Age: 90.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Fatigue, Headache, Nasal congestion, SARS-CoV-2 test
Clinical narrative: headache
Age: 90.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: headache
Age: 90.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Headache
Clinical narrative: headache
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Bell's palsy, Corneal abrasion, Eye movement disorder, Magnetic resonance imaging abnormal
Clinical narrative: developed Bells Palsy on right side of face; corneal abrasions in eyes as a result of not being able to shut eyes fully; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19May2021 at 16:15 as dose 1, single (Lot number: EW0185) at the age of 54 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: VITAMIN C [ASCORBIC ACID]; VITAMIN D NOS; VITAMIN B NOS; MSM [METHYLSULFONYLMETHANE]; BIOTIN. The following information was reported: CORNEAL ABRASION (non-serious) with onset 09Jun2021 at 13:00, outcome "not recovered", described as "corneal abrasions in eyes as a result of not being able to shut eyes fully"; BELL'S PALSY (medically significant) with onset 09Jun2021 at 13:00, outcome "not recovered", described as "developed Bells Palsy on right side of face". The events "developed bells palsy on right side of face" and "corneal abrasions in eyes as a result of not being able to shut eyes fully" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test negative: (11May2022) Negative, notes: Nasal Swab. Therapeutic measures were taken as a result of bell's palsy, corneal abrasion. Adverse event: developed Bells Palsy on right side of face & corneal abrasions in eyes as a result of not being able to shut eyes fully Clinical course: Patient took Vitamin C, D, B, Biotin supplement, & MSM supplement in two weeks and did not take other vaccine in four weeks of COVID vaccination. Patient had no COVID prior to vaccination and she tested with COVID post vaccination.  Follow-up attempts are completed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Bell's palsy, Corneal abrasion, SARS-CoV-2 test negative
Clinical narrative: developed Bells Palsy on right side of face; corneal abrasions in eyes as a result of not being able to shut eyes fully; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19May2021 at 16:15 as dose 1, single (Lot number: EW0185) at the age of 54 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: VITAMIN C [ASCORBIC ACID]; VITAMIN D NOS; VITAMIN B NOS; MSM [METHYLSULFONYLMETHANE]; BIOTIN. The following information was reported: CORNEAL ABRASION (non-serious) with onset 09Jun2021 at 13:00, outcome "not recovered", described as "corneal abrasions in eyes as a result of not being able to shut eyes fully"; BELL'S PALSY (medically significant) with onset 09Jun2021 at 13:00, outcome "not recovered", described as "developed Bells Palsy on right side of face". The events "developed bells palsy on right side of face" and "corneal abrasions in eyes as a result of not being able to shut eyes fully" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test negative: (11May2022) Negative, notes: Nasal Swab. Therapeutic measures were taken as a result of bell's palsy, corneal abrasion. Adverse event: developed Bells Palsy on right side of face & corneal abrasions in eyes as a result of not being able to shut eyes fully Clinical course: Patient took Vitamin C, D, B, Biotin supplement, & MSM supplement in two weeks and did not take other vaccine in four weeks of COVID vaccination. Patient had no COVID prior to vaccination and she tested with COVID post vaccination.  Follow-up attempts are completed. No further information is expected.
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Acute respiratory failure, Blood gases normal, COVID-19, Chest X-ray abnormal, Death
Clinical narrative: Deceased 05/11/2022; Hospitalized 5/11/2022; COVID-19 positive 05/11/2022; fully vaccinated   Discharge Provider: DO Primary Care Physician at Discharge: MD  Admission Date: 5/11/2022  PRESENTING PROBLEM: Acute hypoxemic respiratory failure due to COVID-19 (HCC)    HOSPITAL COURSE: Patient is a 74 year old male with a pmhx of severe COPD with O2 dependent, recent throat cancer on tube feeds, CAD, HTN, HLD, pulmonary HTN, and smoker. Patient had been short of breath and fatigued for the past three days. He was taken to PCP today and found to have 70% O2 saturations on his home 2L. EMS was called placed him on non-rebreather, gave solumedrol, and duoneb. Patient was in respiratory distress upon arrival with RR into the high 30's. He was found to have COVID-19 and CXR was concerning for a superimposed RLL pneumonia.  His initial VBG was ok and he was placed on bipap due to his respiratory distress. Patient then became lethargic, CO2 retention worsened and he became unresponsive.  Daughter stated she feels he has just given up with all he has been through. She has been updating family and she notes that he has made it well known he is to be a DNR/DNI. This is evident from prior hospitalizations. ER provider discussed withdrawing care but more family would like to be present so the patient was admitted to the hospital. Family said goodbyes and bipap O2 therapy was withdrawn. The patient passed away later that evening with family at the bedside. HE was given medications for comfort measures and respiratory dyspnea. Patient passed at 2132
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dyspnoea, Fatigue, Hypercapnia, Lethargy, Positive airway pressure therapy
Clinical narrative: Deceased 05/11/2022; Hospitalized 5/11/2022; COVID-19 positive 05/11/2022; fully vaccinated   Discharge Provider: DO Primary Care Physician at Discharge: MD  Admission Date: 5/11/2022  PRESENTING PROBLEM: Acute hypoxemic respiratory failure due to COVID-19 (HCC)    HOSPITAL COURSE: Patient is a 74 year old male with a pmhx of severe COPD with O2 dependent, recent throat cancer on tube feeds, CAD, HTN, HLD, pulmonary HTN, and smoker. Patient had been short of breath and fatigued for the past three days. He was taken to PCP today and found to have 70% O2 saturations on his home 2L. EMS was called placed him on non-rebreather, gave solumedrol, and duoneb. Patient was in respiratory distress upon arrival with RR into the high 30's. He was found to have COVID-19 and CXR was concerning for a superimposed RLL pneumonia.  His initial VBG was ok and he was placed on bipap due to his respiratory distress. Patient then became lethargic, CO2 retention worsened and he became unresponsive.  Daughter stated she feels he has just given up with all he has been through. She has been updating family and she notes that he has made it well known he is to be a DNR/DNI. This is evident from prior hospitalizations. ER provider discussed withdrawing care but more family would like to be present so the patient was admitted to the hospital. Family said goodbyes and bipap O2 therapy was withdrawn. The patient passed away later that evening with family at the bedside. HE was given medications for comfort measures and respiratory dyspnea. Patient passed at 2132
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Respiratory distress, Unresponsive to stimuli
Clinical narrative: Deceased 05/11/2022; Hospitalized 5/11/2022; COVID-19 positive 05/11/2022; fully vaccinated   Discharge Provider: DO Primary Care Physician at Discharge: MD  Admission Date: 5/11/2022  PRESENTING PROBLEM: Acute hypoxemic respiratory failure due to COVID-19 (HCC)    HOSPITAL COURSE: Patient is a 74 year old male with a pmhx of severe COPD with O2 dependent, recent throat cancer on tube feeds, CAD, HTN, HLD, pulmonary HTN, and smoker. Patient had been short of breath and fatigued for the past three days. He was taken to PCP today and found to have 70% O2 saturations on his home 2L. EMS was called placed him on non-rebreather, gave solumedrol, and duoneb. Patient was in respiratory distress upon arrival with RR into the high 30's. He was found to have COVID-19 and CXR was concerning for a superimposed RLL pneumonia.  His initial VBG was ok and he was placed on bipap due to his respiratory distress. Patient then became lethargic, CO2 retention worsened and he became unresponsive.  Daughter stated she feels he has just given up with all he has been through. She has been updating family and she notes that he has made it well known he is to be a DNR/DNI. This is evident from prior hospitalizations. ER provider discussed withdrawing care but more family would like to be present so the patient was admitted to the hospital. Family said goodbyes and bipap O2 therapy was withdrawn. The patient passed away later that evening with family at the bedside. HE was given medications for comfort measures and respiratory dyspnea. Patient passed at 2132